; and (II) all records within the Veterans Benefits Administration for covered veterans participating in the study. (B) Health outcomes A comparison of health outcomes under subparagraph (A)(ii) shall include an assessment of the following: (i) The reduction or increase in opiate use or dosage. (ii) The reduction or increase in benzodiazepine use or dosage. (iii) The reduction or change in use of other types of medication. (iv) The reduction or increase in alcohol use. (v) The reduction or increase in the prevalence of substance abuse disorders. (vi) Sleep quality. (vii) Osteopathic pain (including pain intensity and pain-related outcomes). (viii) Agitation. (ix) Quality of life. (x) Mortality and morbidity. (xi) Hospital readmissions. (xii) Any newly developed or exacerbated health conditions, including mental health conditions. (b) Implementation Not later than 180 days after the date of the enactment of this Act, the Secretary shall commence the implementation of the study required by subsection (a)(1). (c) Duration of study The study required by subsection (a)(1) shall be carried out for an 18-month period. (d) Report (1) In general Not later than 90 days after the completion of the study required by subsection (a)(1), the Secretary shall submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report on the study. (2) Ability to conduct clinical trials The Secretary shall include in the report required by paragraph (1) an assessment of whether the Secretary is able to meet the criteria necessary to conduct the clinical trials required under section 4, including consideration of subsection (e)(1) of such section. 4. Department of Veterans Affairs clinical trials on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder (a) Clinical trials required (1) In general If the Secretary indicates in the report required by section 3(d) that the Secretary is able to meet the criteria